论文部分内容阅读
雌激素可有效预防妇女绝经后骨质疏松，关于雌激素对骨形成过程的影响尚存争议。我们应用成骨细胞样骨肉瘤细胞株ＵＭＲ－１０６细胞在细胞水平探讨１７β雌二醇（Ｅ２）对骨代谢的调节作用，同时观察新型抗骨质疏松药物ＸＷ６３０对成骨细胞的影响。Ｅ２１０９～１０７ｍｏｌ／Ｌ显著刺激ＵＭＲ－１０６细胞３Ｈ－ＴｄＲ掺入及细胞计数，并使细胞浆及分泌的碱性磷酸酶（ＡＫＰ）活性显著提高。Ｅ２１０－１０ｍｏｌ／Ｌ对ＵＭＲ－１０６细胞增殖及活性无影响。与Ｅ２比较，ＸＷ６３０１Ｏ－１０～１０－７ｍｏｌ／Ｌ均可显著刺激ＵＭＲ－１０６细胞的增殖及活性，且作用强于Ｅ２。结果表明，Ｅ２可刺激成骨细胞增殖及活性，百ＸＷ６３０可能成为治疗骨质疏松的有效药物。
Estrogen can effectively prevent postmenopausal women osteoporosis, estrogen on the bone formation process remains controversial. We used osteoblast-like osteosarcoma cell line UMR-106 cells at the cellular level to explore the regulation of 17β-estradiol (E2) on bone metabolism, and to observe the effect of the new anti-osteoporosis drug XW630 on osteoblasts. E2109 ~ 107mol / L significantly stimulated 3H-TdR incorporation and cell counts in UMR-106 cells, and markedly increased cytosolic and secreted alkaline phosphatase (AKP) activity. E210-10mol / L had no effect on the proliferation and activity of UMR-106 cells. Compared with E2, XW6301O-10 ~ 10-7mol / L could significantly stimulate the proliferation and activity of UMR-106 cells, and stronger than E2. The results show that E2 can stimulate the proliferation and activity of osteoblasts, one hundred XW630 may be an effective drug for the treatment of osteoporosis.